BOLD Boundless Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BOLD matters now
Boundless Bio, Inc. (BOLD) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.41 with -3.98% on the session and $54.2M in market capitalization; recent performance reads 1-month +2.14% and YTD +19.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.6M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -148.2%.
The latest indexable market news headline is "Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Lew Jennifer filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.37
P/S
0.00
EV/EBITDA
-1.15
DCF Value
$-1.46
FCF Yield
-148.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-53.6%
ROA
-39.7%
ROIC
-45.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.6M | $-0.60 |
| Q4 2025 | $0.00 | $-12.9M | $-0.58 |
| FY 2025 | $0.00 | $-58.2M | $-2.60 |
| Q3 2025 | $0.00 | $-13.9M | $-0.62 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.97
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.